Integrated BioPharma reported a decline in revenue and a shift to an operating loss for both the quarter and six-month period ended December 31, 2025. The company's performance was impacted by decreased sales, particularly from its largest customers.
No highlights available
Revenue for the quarter ended December 31, 2025 was $11.3 million, a decrease of 10.3% compared to $12.6 million in the prior year quarter.
negativeThe company reported an operating loss of $0.9 million for the quarter ended December 31, 2025, compared to an operating income of $0.2 million in the prior year quarter.
negativeRevenue for the six-month period ended December 31, 2025 was $24.0 million, a decrease of 8.4% compared to $26.2 million in the prior year period.
negativeThe company had an operating loss of $0.7 million for the six-month period ended December 31, 2025, compared to an operating income of $0.7 million in the prior year period.
negativeNet loss for the quarter was $0.8 million, with a diluted loss per share of $(0.03), compared to a net income of $0.1 million and $0.00 diluted EPS in the prior year quarter.
negativeRevenue from the two largest customers in the Contract Manufacturing Segment represented approximately 89% of total revenue in the six months ended December 31, 2025, indicating high customer concentration.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
Revenue decreased by approximately 8% in the six-month period ended December 31, 2025 from the six-month period ended December 31, 2024.
Revenue from the two largest customers in our Contract Manufacturing Segment represented approximately 89% and 82% of total revenue in the six months ended December 31, 2025 and 2024, respectively.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.